

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) <u>RESUBMISSION OF</u> PTO Form 1449 December 4, 2008				Attorney Docket No. 056291-5215		Application No. 10/554,202			
				Applicants: Robert Hugh BRADBURY <i>et al.</i>					
				Filing Date: October 24, 2005		Group Art Unit: 1624			
U.S. PATENT DOCUMENTS									
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date		
/T.N./	1.	US 2003/0186995	October 2, 2003	Kath et al.					
/T.N./	2.	US 2004/0048880	March 11, 2004	Himmelsbach et al.					
FOREIGN PATENT DOCUMENTS									
		Document No.	Date	Country	Inventor/Assignee		Translation		
/T.N./	3.	CA 2476008	October 9, 2003	Canada	Boehringer Ingelheim Pharma				
/T.N./	4.	CA 2543649	May 12, 2005	Canada	Boehringer Ingelheim International GmbH				
/T.N./	5.	WO 01/21596	March 29, 2001	WIPO	AstraZeneca AB				
/T.N./	6.	WO 2004/046101	June 3, 2004	WIPO	Array Biopharma Inc.				
/T.N./	7.	WO 2005/041973	May 12, 2005	WIPO	Boehringer Ingelheim International GmbH				
/T.N./	8.	WO 2005/097134	October 20, 2005	WIPO	The Scripps Research Institute				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)									
/T.N./	9.	Ballard et al. "Developing a small molecule erbB2 inhibitor: challenges with optimising DMPK properties" Poster - Presented at DMDG Cambridge (February 6, 2008).							
/T.N./	10.	Ballard et al. "Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorg Med Chem Lett. 17(22):6326-6329 (2007).							
/T.N./	11.	Barlaam et al. "A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorganic & Medicinal Chemistry Letters 18(2):674-678 (2008).							
/T.N./	12.	Barlaam et al. "Indazolylamino/Anilinoquinazolines Bearing a C-5 substitution as erbB2 kinase inhibitors: Structure-activity relationships and identification of a candidate drug" at AACR in 2007							
/T.N./	13.	Barlaam et al. "Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorganic & Medicinal Chemistry Letters 18(6):1799-1803 (2008).							
/T.N./	14.	Barlaam et al. "Indazolylamino/Anilinoquinazolines Bearing a C-5 Substitution As erbB2 Kinase Inhibitors: Structure-Activity Relationships and Identification of a Candidate Drug" Poster number P044, presented at XXth International Symposium on Medicinal Chemistry (EFMC-ISMIC 2008), Vienna, Austria, August 31 - September 4, 2008.							
/T.N./	15.	Cockerill et al. "Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFR and c-erbB-2" Bioorganic & Medicinal Chemistry Letters 11(11):1401-1405 (2001).							
/T.N./	16.	Ducray et al. "Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors" Bioorganic & Medicinal Chemistry Letters 18(3):959-962 (2008).							
/T.N./	17.	Gaul et al. "Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines" Bioorganic & Medicinal Chemistry Letters 13(4):637-640 (2003).							
/T.N./	18.	Harris et al. "Systematic variation of a key quinazoline core" Presented at the XXII European Colloquium on Heterocyclic Chemistry (XXII ECHC-2006) Bari, Italy, September 2-6, 2006.							
/T.N./	19.	Hennequin et al. "N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor" J Med Chem. 49(22):6465-6488 (2006).							
/T.N./	20.	Jani et al. "Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor" Cancer Research 67(20):9887-9893 (2007).							
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 40%;"> Examiner <div style="text-align: center;">/Tamthom Truong/</div> </td> <td style="width: 60%;"> Date Considered <div style="text-align: center;">08/12/2009</div> </td> </tr> </table>								Examiner <div style="text-align: center;">/Tamthom Truong/</div>	Date Considered <div style="text-align: center;">08/12/2009</div>
Examiner <div style="text-align: center;">/Tamthom Truong/</div>	Date Considered <div style="text-align: center;">08/12/2009</div>								
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) <u>RESUBMISSION OF</u> PTO Form 1449 December 4, 2008				Attorney Docket No. 056291-5215		Application No. 10/554,202	
				Applicants: Robert Hugh BRADBURY <i>et al.</i>			
				Filing Date: October 24, 2005		Group Art Unit: 1624	
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
/T.N./	21.	Klutchko et al. "Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors" J Med Chem. 49(4):1475-1485 (2006) .					
/T.N./	22.	Petrov et al. "Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series" Bioorg Med Chem Lett. 16(17):4686-4691 (2006) .					
Examiner		/Tamthom Truong/		Date Considered		08/12/2009	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) <u>RESUBMISSION OF</u> PTO Form 1449 June 8, 2007				Attorney Docket No. 056291-5215		Application No. 10/554,202	
				Applicants: BRADBURY et al.			
				Filing Date: October 24, 2005		Group Art Unit: 1624	
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
/T.N./	1.	US 4,335,127	June 15, 1982	Vandenberk et al.			
/T.N./	2.	US 4,921,863	May 1, 1990	Sugimoto et al.			
/T.N./	3.	US 6,297,258	October 2, 2001	Wissner et al.			
/T.N./	4.	US 6,562,319	May 13, 2003	Mishani et al.			
/T.N./	5.	US 6,972,288	December 6, 2005	Himmelsbach et al.			
/T.N./	6.	US 20020082270	June 27, 2002	Himmelsbach et al.			
/T.N./	7.	US 20020128553	September 12, 2002	Mishani et al.			
/T.N./	8.	US 20040176361	September 9, 2004	Fujio et al.			
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Inventor/Assignee		Translation
/T.N./	9.	EP 0288563	November 2, 1988	EPO	Eisai Co., Ltd.		
/T.N./	10.	EP 1230919	August 14, 2002	EPO	Warner-Lambert Company		
/T.N./	11.	EP 1369418	December 10, 2003	EPO	Mitsubishi Pharma Corporation		
/T.N./	12.	WO 88/02365	April 7, 1988	WIPO	Eisai Co., Ltd.		US 4,921,863
/T.N./	13.	WO 99/06378	February 11, 1999	WIPO	Warner-Lambert Company		
/T.N./	14.	WO 00/09481	February 24, 2000	WIPO	Takeda Chemical Industries, Ltd.		Claims
/T.N./	15.	WO 00/18740	April 6, 2000	WIPO	American Cyanamid Company		
/T.N./	16.	WO 00/24718	May 4, 2000	WIPO	Akzo Nobel N.V.		
/T.N./	17.	WO 01/07432	February 1, 2001	WIPO	Smithkline Beecham P.L.C.		
/T.N./	18.	WO 01/21597	March 29, 2001	WIPO	AstraZeneca AB		
/T.N./	19.	WO 02/056882	July 25, 2002	WIPO	Smithkline Beecham P.L.C.		
/T.N./	20.	WO 02/062767	August 15, 2002	WIPO	Japan Energy Corporation		Yes
/T.N./	21.	WO 02/066445	August 29, 2002	WIPO	Mitsubishi Pharma Corporation		EP 1369418
/T.N./	22.	WO 02/068409	September 6, 2002	WIPO	Merck & Co., Inc.		
/T.N./	23.	WO 02/073235	September 19, 2002	WIPO	Yissum Research Development Company of The Hebrew University Of Jerusalem		
/T.N./	24.	WO 02/076976	October 3, 2002	WIPO	Bayer Corporation		
/T.N./	25.	WO 02/092577	November 21, 2002	WIPO	AstraZeneca AB		
/T.N./	26.	WO 02/092578	November 21, 2002	WIPO	AstraZeneca AB		
/T.N./	27.	WO 02/094790	November 28, 2002	WIPO	Mitsubishi Pharma Corporation		US 2004176361
/T.N./	28.	WO 02/24684	March 28, 2002	WIPO	Smithkline Beecham P.L.C.		
/T.N./	29.	WO 02/30924	April 18, 2002	WIPO	AstraZeneca AB		
/T.N./	30.	WO 02/34744	May 2, 2002	WIPO	AstraZeneca AB		
/T.N./	31.	WO 02/44166	June 6, 2002	WIPO	AstraZeneca AB		
/T.N./	32.	WO 02/48117	June 20, 2002	WIPO	Fujisawa Pharmaceutical Co., Ltd.		
/T.N./	33.	WO 03/049740	June 19, 2003	WIPO	Pfizer Products Inc.		
/T.N./	34.	WO 04/064718	August 5, 2004	WIPO	T.K. Signal Ltd.		
/T.N./	35.	WO 06/092573	September 8, 2006	WIPO	AstraZeneca AB		
/T.N./	36.	WO 06/092574	September 8, 2006	WIPO	AstraZeneca AB		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
Examiner		/Tamthom Truong/		Date Considered		08/12/2009	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) <u>RESUBMISSION OF</u> PTO Form 1449 February 27, 2007				Attorney Docket No. 056291-5215		Application No. 10/554,202	
				Applicants: BRADBURY <i>et al.</i>			
				Filing Date: October 24, 2005		Group Art Unit: 1624	
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
/T.N./	1.	US 4,322,420	March 30, 1982	Kobayashi et al.	514	266.4	September 11, 1979
/T.N./	2.	US 4,640,920	February 3, 1987	Boyle et al.	514	248	June 13, 1985
/T.N./	3.	US 5,405,843	April 11, 1995	Fukazawa et al.	514	183	September 9, 1993
/T.N./	4.	US 5,721,237	February 24, 1998	Myers et al.	514	266.1	June 6, 1995
/T.N./	5.	US 5,747,498	May 5, 1998	Schnur et al.	514	266.4	May 28, 1996
/T.N./	6.	US 5,929,080	July 27, 1999	Frost	514	266.4	April 21, 1998
/T.N./	7.	US 5,962,458	October 5, 1999	Lohmann et al.	514	266.21	December 17, 1996
/T.N./	8.	US 6,004,967	December 21, 1999	McMahon et al.	514	266.4	September 11, 1997
/T.N./	9.	US 6,046,206	April 4, 2000	Pamukcu et al.	514	266.21	April 30, 1997
/T.N./	10.	US 6,117,433	September 12, 2000	Edens et al.	424	400	April 28, 1998
/T.N./	11.	US 6,313,130	November 6, 2001	Uckun et al.	514	266.24	July 28, 2000
/T.N./	12.	US 6,326,373	December 4, 2001	Uckun et al.	514	266.1	October 16, 2000
/T.N./	13.	US 6,384,223	May 7, 2002	Gletsos	544	293	May 4, 2000
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Inventor/Assignee		Translation
/T.N./	14.	EP 0 326 330	July 24, 2002	EPA	Dow AgroSciences LLC		
/T.N./	15.	EP 0 520 722	December 27, 1996	EPA	Zeneca Limited		
/T.N./	16.	EP 0 566 226	November 8, 1995	EPA	Zeneca Limited		
/T.N./	17.	EP 0 602 851	October 9, 1996	EPA	Zeneca Limited		
/T.N./	18.	EP 0 787 722	August 6, 1997	EPA	American Cyanamid Company		
/T.N./	19.	EP 0 837 063	April 22, 1998	EPA	Pfizer Inc.		
/T.N./	20.	GB 2,295,387	May 29, 1996	United Kingdom	Glaxo Inc		
/T.N./	21.	JP-08-003144	January 17, 1996	Japan	Chugai Pharmaceut Co Ltd		Abstract
/T.N./	22.	JP-11-189586	July 13, 1999	Japan	Kirin Brewery Co Ltd		Abstract
/T.N./	23.	WO 92/20642	November 26, 1992	WIPO	Rhone-Poulenc Rorer Inter. Inc.		
/T.N./	24.	WO 93/08170	April 29, 1993	WIPO	American Home Products Corp.		
/T.N./	25.	WO 93/17682	September 16, 1993	WIPO	Abbott Laboratories		
/T.N./	26.	WO 95/15758	June 15, 1995	WIPO	Rhone-Poulenc Rorer Pharma. Inc.		
/T.N./	27.	WO 96/09294	March 28, 1996	WIPO	The Wellcome Foundation Limited		
/T.N./	28.	WO 96/15118	May 23, 1996	WIPO	Zeneca Limited		
/T.N./	29.	WO 96/16960	June 6, 1996	WIPO	Zeneca Limited		
/T.N./	30.	WO 96/30347	October 3, 1996	WIPO	Pfizer Inc.		
/T.N./	31.	WO 96/33977	October 31, 1996	WIPO	Zeneca Limited		
/T.N./	32.	WO 96/33978	October 31, 1996	WIPO	Zeneca Limited		
/T.N./	33.	WO 96/33979	October 31, 1996	WIPO	Zeneca Limited		
/T.N./	34.	WO 96/33980	October 31, 1996	WIPO	Zeneca Limited		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
Examiner		/Tamthom Truong/		Date Considered		08/12/2009	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) <u>RESUBMISSION OF</u> PTO Form 1449 February 27, 2007				Attorney Docket No. 056291-5215		Application No. 10/554,202	
				Applicants: BRADBURY <i>et al.</i>			
				Filing Date: October 24, 2005		Group Art Unit: 1624	
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Inventor/Assignee	Translation	
/T.N./	35.	WO 96/33981	October 31, 1996	WIPO	Zeneca Limited		
/T.N./	36.	WO 96/39145	December 12, 1996	WIPO	Rhone-Poulenc Rorer Pharmaceuticals Inc.		
/T.N./	37.	WO 97/03069	January 30, 1997	WIPO	Glaxo Group Limited		
/T.N./	38.	WO 97/11692	April 3, 1997	WIPO	Osteoarthritis Sciences, Inc.		
/T.N./	39.	WO 97/13771	April 17, 1997	WIPO	Glaxo Group Limited		
/T.N./	40.	WO 97/22596	June 26, 1997	WIPO	Zeneca-Pharma S.A.		
/T.N./	41.	WO 97/30034	August 21, 1997	WIPO	Zeneca Limited		
/T.N./	42.	WO 97/30035	August 21, 1997	WIPO	Zeneca Pharma S.A.		
/T.N./	43.	WO 97/30044	August 21, 1997	WIPO	Zeneca Limited		
/T.N./	44.	WO 97/38983	October 23, 1997	WIPO	Warner-Lambert Company		
/T.N./	45.	WO 97/38994	October 23, 1997	WIPO	Zeneca Limited		
/T.N./	46.	WO 98/02434	January 22, 1998	WIPO	Glaxo Group Limited		
/T.N./	47.	WO 98/02437	January 22, 1998	WIPO	Glaxo Group Limited		
/T.N./	48.	WO 98/02438	January 22, 1998	WIPO	Glaxo Group Limited		
/T.N./	49.	WO 98/13354	April 2, 1998	WIPO	Zeneca Pharma S.A.		
/T.N./	50.	WO 98/38984	September 11, 1998	WIPO	Sugen, Inc.		
/T.N./	51.	WO 98/50038	November 12, 1998	WIPO	American Cyanamid Company		
/T.N./	52.	WO 98/50370	November 12, 1998	WIPO	Sugen, Inc.		
/T.N./	53.	WO 99/09016	February 25, 1999	WIPO	American Cyanamid Company		
/T.N./	54.	WO 99/24037	May 20, 1999	WIPO	American Cyanamid Company		
/T.N./	55.	WO 99/35132	July 15, 1999	WIPO	Glaxo Group Limited		
/T.N./	56.	WO 99/35146	July 15, 1999	WIPO	Glaxo Group Limited		
/T.N./	57.	WO 99/61428	December 2, 1999	WIPO	Parker Hughes Institute		
/T.N./	58.	WO 00/00202	January 6, 2000	WIPO	Uckun, Fatih, M.		
/T.N./	59.	WO 00/06555	February 10, 2000	WIPO	American Home Products Corporation		
/T.N./	60.	WO 00/10981	March 2, 2000	WIPO	Parker Hughes Institute		
/T.N./	61.	WO 00/20402	April 13, 2000	WIPO	Zeneca Limited		
/T.N./	62.	WO 00/44728	August 3, 2000	WIPO	Pfizer Products Inc.		
/T.N./	63.	WO 00/47212	August 17, 2000	WIPO	Zeneca-Pharma S.A.		
/T.N./	64.	WO 00/51587	September 8, 2000	WIPO	Parker Hughes Institute		
/T.N./	65.	WO 00/51991	September 8, 2000	WIPO	Boehringer Ingelheim Pharma KG		
/T.N./	66.	WO 00/55141	September 21, 2000	WIPO	Boehringer Ingelheim Pharma KG		
/T.N./	67.	WO 00/73260	December 7, 2000	WIPO	Celltech Chiroscience Limited		
/T.N./	68.	WO 01/12227	February 22, 2001	WIPO	American Cyanamid Company		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
Examiner		/Tamthom Truong/		Date Considered		08/12/2009	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) <u>RESUBMISSION OF</u> PTO Form 1449 February 27, 2007				Attorney Docket No. 056291-5215		Application No. 10/554,202	
				Applicants: BRADBURY <i>et al.</i>			
				Filing Date: October 24, 2005		Group Art Unit: 1624	
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Inventor/Assignee	Translation	
/T.N./	69.	WO 01/21594	March 29, 2001	WIPO	AstraZeneca AB		
/T.N./	70.	WO 01/21595	March 29, 2001	WIPO	AstraZeneca AB		
/T.N./	71.	WO 01/32632	May 10, 2001	WIPO	Eli Lilly And Company		
/T.N./	72.	WO 01/45641	June 28, 2001	WIPO	Parker Hughes Institute		
/T.N./	73.	WO 01/77085	October 18, 2001	WIPO	AstraZeneca AB		
/T.N./	74.	WO 01/94341	December 13, 2001	WIPO	AstraZeneca AB		
/T.N./	75.	WO 01/98277	December 27, 2001	WIPO	Pfizer Products Inc.		
/T.N./	76.	WO 02/18372	March 7, 2002	WIPO	Boehringer Ingelheim Pharma KG	Abstract	
/T.N./	77.	WO 02/41882	May 30, 2002	WIPO	NOVARTIS AG		
/T.N./	78.	WO 03/040108	May 15, 2003	WIPO	AstraZeneca AB		
/T.N./	79.	WO 03/040109	May 15, 2003	WIPO	AstraZeneca AB		
/T.N./	80.	WO 03/082290	October 9, 2003	WIPO	Boehringer Ingelheim Pharma Gmbh & Co.		
/T.N./	81.	WO 03/082831	October 9, 2003	WIPO	AstraZeneca AB		
/T.N./	82.	WO 2004/006846	January 22, 2004	WIPO	Exelixis, Inc.		
/T.N./	83.	WO 2004/096226	November 11, 2004	WIPO	AstraZeneca AB		
/T.N./	84.	WO 2005/012290	November 4, 2004	WIPO	AstraZeneca AB		
/T.N./	85.	WO 2005/013998	February 17, 2005	WIPO	AstraZeneca AB		
/T.N./	86.	WO 2005/026150	March 24, 2005	WIPO	AstraZeneca AB		
/T.N./	87.	WO 2005/026151	March 24, 2005	WIPO	AstraZeneca AB		
/T.N./	88.	WO 2005/026152	March 24, 2005	WIPO	AstraZeneca AB		
/T.N./	89.	WO 2005/026156	March 24, 2005	WIPO	AstraZeneca AB		
/T.N./	90.	WO 2005/026157	March 24, 2005	WIPO	AstraZeneca AB		
/T.N./	91.	WO 2005/028469	March 31, 2005	WIPO	AstraZeneca AB		
/T.N./	92.	WO 2005/028470	March 31, 2005	WIPO	AstraZeneca AB		
/T.N./	93.	WO 2005/030757	April 7, 2005	WIPO	AstraZeneca AB		
/T.N./	94.	WO 2005/030765	April 7, 2005	WIPO	AstraZeneca AB		
/T.N./	95.	WO 2005/051923	June 9, 2005	WIPO	AstraZeneca AB		
/T.N./	96.	WO 2005/075439	August 18, 2005	WIPO	AstraZeneca AB		
/T.N./	97.	WO 2005/118572	December 15, 2005	WIPO	AstraZeneca AB		
/T.N./	98.	WO 2006/008526	January 26, 2006	WIPO	AstraZeneca AB		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
/T.N./	99.	Ballard et al. "5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorg Med Chem Lett. 15(19):4226-4229 (2005).					
/T.N./	100.	Ballard et al. "Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket" Bioorg Med Chem Lett. 16(6):1633-1637 (2006).					
Examiner		/Tamthom Truong/		Date Considered		08/12/2009	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) <u>RESUBMISSION OF</u> PTO Form 1449 February 27, 2007				Attorney Docket No. 056291-5215		Application No. 10/554,202	
				Applicants: BRADBURY et al.			
				Filing Date: October 24, 2005		Group Art Unit: 1624	
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
/T.N./	101.	Ballard et al. "Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics" <i>Bioorg Med Chem Lett.</i> 16(18):4908-4912 (2006) .					
/T.N./	102.	Barker et al. "Studies leading to the identification of ZD1839 (Iressa TM): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer" <i>Bioorganic and Medicinal Chemistry Letters</i> 11(14):1911-1914 (2001) .					
/T.N./	103.	Bridges et al. "Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor" <i>J. Med. Chem.</i> 39(1):267-276 (1996) .					
/T.N./	104.	Denny et al. "Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site for the epidermal growth factor receptor in vitro" <i>Clinical and Experimental Pharmacology and Physiology</i> 23:424-427 (1996).					
/T.N./	105.	Harris et al. "Facile synthesis of 7-amino anilinoquinazolines via direct amination of the quinazoline core" <i>Tetrahedron letters</i> 46(43): 7381-7384 (2005) .					
/T.N./	106.	Harris et al. "Selective alkylation of a 6,7-dihydroxyquinazoline" <i>Tetrahedron letters</i> 46(45):7715-7719 (2005).					
/T.N./	107.	Hennequin et al. "Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors" <i>Bioorg Med Chem Lett.</i> 16(10):2672-2676 (2006) .					
/T.N./	108.	Hennequin et al. "Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors" <i>J. Med. Chem.</i> 45 (6):1300 -1312 (2002) .					
/T.N./	109.	Rewcastle et al. "Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor" <i>J. Med. Chem.</i> 38:3482-3487 (1995) .					
/T.N./	110.	Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor" <i>J. Biol. Chem.</i> 277(48):46265-46272 (2002) .					
/T.N./	111.	Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" <i>Exp. Opin. Ther. Patents</i> 7(6):571-588 (1997) .					
/T.N./	112.	Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" <i>Exp. Opin. Ther. Patents</i> 8(12):1599-1625 (1998) .					
/T.N./	113.	Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" <i>J. Med. Chem.</i> 44:2719-2734 (2001) .					
/T.N./	114.	Vema et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" <i>Bioorg Med Chem.</i> 11(21):4643-4653 (2003) .					
Examiner		/Tamthom Truong/		Date Considered		08/12/2009	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) <u>RESUBMISSION OF</u> PTO Form 1449 October 24, 2005	ATTY DOCKET NO. 056291-5215-US	APPLICATION NO To be assigned
	APPLICANT Robert Hugh BRADBURY et al.	
	FILING DATE October 24, 2005	GROUP XXXXXXXXXX 1624 To be assigned

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	INVENTOR/ASSIGNEE	TRANSLATION	
						YES	NO
/T.N./	B01	WO 96/15118	05/1996	PCT	Zeneca Limited		
/T.N./	B02	WO 03/040108	05/2003	PCT	AstraZeneca AB		
	B03						
	B04						
	B05						

EXAMINER	/Tamthom Truong/	DATE CONSIDERED	08/12/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			